Vancomycin — Membership Pricing

Other medications in Infections

• Velpatasvir
• Voriconazole
• Zanamivir
• Zidovudine
• Abacavir
• Acyclovir
• Adefovir
• Atazanavir

About Vancomycin

Vancomycin is a critical antibiotic used to treat severe bacterial infections, including those resistant to other medications. Its powerful action makes it a cornerstone in modern medicine. At TheDrugClub, we understand the importance of affordable access to essential treatments like vancomycin, offering members significant savings on their prescriptions.

Vancomycin is a powerful antibiotic primarily reserved for treating serious bacterial infections that are resistant to other, more common antibiotics. It's frequently prescribed for infections caused by methicillin-resistant *Staphylococcus aureus* (MRSA), which can lead to severe skin infections, bloodstream infections, pneumonia, and bone infections. Additionally, oral vancomycin is a key treatment for *Clostridioides difficile* (C. diff)-associated diarrhea, a challenging intestinal infection

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Vancomycin is approved for (FDA label)

TYZAVAN is a glycopeptide antibacterial indicated for the treatment of the following infections in adult and pediatric patients (1 month and older) for whom appropriate dosing with this formulation can be achieved: Septicemia ( 1.1 ) Infective Endocarditis ( 1.2 ) Skin and Skin Structure Infections ( 1.3 ) Bone Infections ( 1.4 ) Lower Respiratory Tract Infections ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of TYZAVAN and other antibacterial drugs, TYZAVAN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Septicemia TYZAVAN is indicated in adults and pediatric patients (1 month and older) for whom appropriate dosing with this formulation can be achieved [see Dosage and Administration (2) and Use in Specific Populations (8.4) ] for the treatment of septicemia due to: Susceptible isolates of methicillin-resistant Staphylococcus aureus (MRSA) and coagulase negative staphylococci.

Source: Read the full FDA label on DailyMed. Label effective date: August 19, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Vancomycin (FDA label)

Injection: TYZAVAN (Vancomycin Injection, USP) is a ready to use clear, colorless to light brown sterile solution in single-dose flexible bags in the following strengths: 500 mg vancomycin in 100 mL (5 mg/mL), 750 mg vancomycin in 150 mL (5 mg/mL), 1 g vancomycin in 200 mL (5 mg/mL), 1.25 g vancomycin in 250 mL (5 mg/mL), 1.5 g vancomycin in 300 mL (5 mg/mL), 1.75 g vancomycin in 350 mL (5 mg/mL) and 2 g vancomycin in 400 mL (5mg/mL) of Water for Injection [see Description (11) ] . Injection: TYZAVAN contains 500 mg vancomycin in 100 mL, 750 mg vancomycin in 150 mL, 1 g vancomycin in 200 mL, 1.25 g vancomycin in 250 mL, 1.5 g vancomycin in 300 mL, 1.75 g vancomycin in 350 mL and 2 g vancomycin in 400 mL (5 mg/mL) of Water for Injection in single-dose flexible bags. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 72e9c5e2-07cc-4a8b-ba64-b2e7619ea560. SPL document ID: 7bddeff1-1858-437c-b772-b063a7e7c6f8. Label effective date: August 19, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Vancomycin (FDA label)

The following clinically significant adverse reactions are described elsewhere in the labeling: Infusion Reactions [see Warnings and Precautions (5.1) ] Nephrotoxicity [see Warnings and Precautions (5.2) ] Ototoxicity [see Warnings and Precautions (5.3) ] Severe Dermatologic Reactions [see Warnings and Precautions (5.4) ] Clostridioides Difficile -Associated Diarrhea [see Warnings and Precautions (5.5) ] Hemorrhagic Occlusive Retinal Vasculitis [see Warnings and Precautions (5.6) ] Neutropenia [see Warnings and Precautions (5.7) ] Phlebitis and Other Administration Site Reactions [see Warnings and Precautions (5.8) ] The most common adverse reactions are anaphylaxis, “vancomycin infusion reactions”, acute kidney injury, hearing loss, neutropenia. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-877-845-0689 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 72e9c5e2-07cc-4a8b-ba64-b2e7619ea560. SPL document ID: 7bddeff1-1858-437c-b772-b063a7e7c6f8. Label effective date: August 19, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Vancomycin (FDA label)

TYZAVAN is contraindicated in patients with known hypersensitivity to vancomycin. Hypersensitivity to vancomycin ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 72e9c5e2-07cc-4a8b-ba64-b2e7619ea560. SPL document ID: 7bddeff1-1858-437c-b772-b063a7e7c6f8. Label effective date: August 19, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Vancomycin (FDA label)

Infusion Reactions : Hypotension, including shock and cardiac arrest, wheezing, dyspnea, urticaria, muscular and chest pain and “vancomycin infusion reactions” which manifests as pruritus and erythema that involves the face, neck and upper body may occur with rapid intravenous administration. To reduce the risk of infusion reactions, administer TYZAVAN over a period of 60 minutes or greater and also prior to intravenous anesthetic agents. ( 2.1, 5.1 ) Nephrotoxicity : Monitor renal function in all patients receiving TYZAVAN. ( 5.2 ) Ototoxicity : Serial tests of auditory function may be helpful. ( 5.3 ) Severe Dermatologic Reactions : Discontinue TYZAVAN at the first appearance of signs and symptoms of TEN, SJS, DRESS, AGEP, or LABD. ( 5.4 ) Clostridioides difficile -Associated Diarrhea (CDAD) : Evaluate patients if diarrhea occurs. ( 5.5 ).

Source: FDA prescribing information (DailyMed). Set ID: 72e9c5e2-07cc-4a8b-ba64-b2e7619ea560. SPL document ID: 7bddeff1-1858-437c-b772-b063a7e7c6f8. Label effective date: August 19, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Vancomycin (FDA label)

Anesthetic Agents : Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing. ( 2.1 , 7.1 ) Piperacillin/Tazobactam : Increased incidence of acute kidney injury in patients receiving concomitant piperacillin/tazobactam and vancomycin as compared to vancomycin alone. Monitor kidney function in patients. ( 7.2 ) 7.1 Anesthetic Agents Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing [see Warnings and Precautions (5.1) and Use in Specific Populations (8.4) ] . 7.2 Piperacillin-Tazobactam Studies have detected an increased incidence of acute kidney injury in patients administered concomitant piperacillin/tazobactam and vancomycin as compared to vancomycin alone.

Source: FDA prescribing information (DailyMed). Set ID: 72e9c5e2-07cc-4a8b-ba64-b2e7619ea560. SPL document ID: 7bddeff1-1858-437c-b772-b063a7e7c6f8. Label effective date: August 19, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.